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Risk factors for low adherence 
to methylphenidate 
treatment in pediatric patients 
with attention‑deficit/hyperactivity 
disorder
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Genichi Sugihara1, Shingo Kitamura3 & Kazuo Mishima2,3,5*
Poor adherence is a major concern in the treatment of attention‑deficit/hyperactivity disorder (ADHD). 
The objective of this study was to evaluate factors linked to early interruption of and low adherence 
to treatment with osmotic‑release oral system methylphenidate hydrochloride (OROS‑MPH) in 
pediatric patients with ADHD. A total of 1353 young people (age 6–17 years) with a diagnosis of ADHD 
who newly started OROS‑MPH were extracted from the pharmacoepidemiological data of 3 million 
people in Japan. The cohort was retrospectively surveyed every month for 12 months. Ten possible 
risk factors were extracted from the data and analyzed by multivariable logistic regression. Sensitivity 
analysis was conducted to ensure the robustness of the analysis. The results revealed that treatment 
adherence was generally poor, with a tendency for discontinuation in the early stage. Multivariable 
logistic regression results showed that adherence is reduced by female sex, lower starting dose, and 
concomitant atomoxetine or hypnotics. These findings may help clinicians to predict the risk of poor 
adherence in the early stage of treatment and improve not only patients’ symptoms, but also their 
quality of life.
Attention-deficit/hyperactivity disorder (ADHD) is a common chronic neurodevelopmental disorder charac-
terized by symptoms of inattention, hyperactivity, and impulsivity. Individuals with ADHD are at high risk of 
comorbid psychiatric disorders, such as oppositional defiant disorder, conduct disorders, depression, bipolar 
disorders, and anxiety  disorders1. The onset of ADHD occurs mostly in childhood, but 50% to 80% of diagnosed 
children continue to demonstrate ADHD symptoms into adolescence or  adulthood2–5. The symptoms of ADHD 
and comorbid disorders can impair an individual’s ability to function in social circumstances, resulting in aca-
demic, familial, and social  problems6,7.
In the latest Japanese guidelines for the diagnosis and treatment of ADHD, released in  20168, the management 
of children with ADHD should begin with psychosocial treatment. Additional administration of pharmacological 
therapy should be considered when psychosocial treatments are insufficient. However, as shown by fact-finding 
surveys on pharmacotherapy for ADHD, most physicians support the need for  pharmacotherapy9.
Four types of ADHD medication are currently available in Japan: osmotic-release oral system methylpheni-
date hydrochloride (OROS-MPH, CONCERTA), atomoxetine (ATX, STRATTERA), guanfacine hydrochloride 
(INTUNIV), and lisdexamfetamine dimesylate (VYVANSE). Of these medications, OROS-MPH is the most 
prescribed. Due to its addictive profile, the circulation management committee strictly controlled its prescrip-
tion by limiting prescribers’ certification and the prescription duration until the ADHD proper distribution 
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management system is established in December 2019. Accordingly, there is a high likelihood of proper prescrip-
tion of OROS-MPH in Japan.
The latest Japanese  guidelines8 recommended that termination of medication be considered when patients 
are stable for more than 1 year after they obtain a score of 61 or above on the Global Assessment of Functioning 
(GAF) scale. Therefore, patients need to adhere to the prescribed treatment regimens for at least 1 year.
Despite the high reliability of proper prescription of OROS-MPH medication in Japan because of its strict 
control, there is an issue with patients’ unstable patterns of outpatient visits and oral intake in clinical practice. 
This leads to poor adherence or discontinuation of the treatment in the early stage, which could limit treatment 
effects and increase the risk of comorbid psychiatric disorders. There is a considerable need to understand the 
prescription patterns of ADHD medications and to identify risk factors associated with poor adherence in order 
to help patients to adhere to their recommended treatment regimen and to facilitate proper intervention. How-
ever, to our knowledge, no study has examined the actual prescription patterns of OROS-MPH and analyzed 
the possible factors associated with poor adherence in Japan. Therefore, in this study, we evaluated the current 
prescription trend of OROS-MPH in pediatric ADHD patients in Japan. We also analyzed the factors that could 
predict poor adherence in the early stage of the treatment, based on data from the claims database.
Methods
All procedures were performed in accordance with the ethical guidelines for epidemiological research issued 
by the Japanese Ministry of Health, Labour and Welfare. This study was approved by the Ethics Committee of 
Akita University Graduate School of Medicine, Akita, Japan, which waived the requirement for obtaining writ-
ten informed consent.
Data source. The data used in this research were provided by JMDC Inc. (Tokyo, Japan). JMDC Inc. has 
been collecting claims information from occupation-based health insurance agencies for corporate employees 
and their dependents since  200510. All health insurance data included in the JMDC database are anonymized, 
and permission for secondary use of the data has been obtained from the subscriber.
The number of individuals registered in JMDC is about 3 million, which is approximately 2.5% of the entire 
Japanese population as of June 2016. Each record includes an encrypted personal identifier, age, sex, diagnoses, 
and prescriptions. The diagnoses are based on International Statistical Classification of Diseases and Related 
Health Problems, 10th revision (ICD-10) diagnostic codes. The prescription information includes WHO Ana-
tomical Therapeutic Chemical (WHO-ATC) classification system codes, drug name, days of supply, dosage 
information, and mode of prescription. The date of service is specified up to the month and year.
Study population. We selected outpatients who were 6 to 17 years when they were first prescribed OROS-
MPH between December 2007 and May 2015. We selected only new users who had not been prescribed MPH 
within 1 year prior to their first prescription during our observation period. Then, we extracted individuals who 
could be observed for at least 1 year. We also excluded individuals who had a diagnosis of narcolepsy because 
they are prescribed methylphenidate hydrochloride and not OROS-MPH. A total of 1353 children were included 
in this study (Fig. 3).
Study variables. Patient persistence and adherence. Medication compliance has two indicators: “persis-
tence” and “adherence”. Persistence is usually calculated by the period until the discontinuation of the initial 
treatment. In this study, the discontinuation of the medication was defined as the beginning of a gap of more 
than 3 months in prescriptions for OROS-MPH. We named this gap period GAP3M in this study. On the other 
hand, adherence was assessed using the MPR, which reflects the proportion of months that patients were in pos-
session of the medication within a specific period. We calculated the MPR by summing the number of months 
in which patients received their prescription and dividing it by the follow-up period in months (12 months). The 
conventional 50% cutoff was used.
Risk factors. We selected the possible risk factors that might interfere with medication adherence. As men-
tioned in previous studies, many factors are related to medication continuation and adherence. These include 
specific child and adolescent characteristics, such as  age11–16, male  sex11, and ethnic  background13, clinical char-
acteristics, such as symptom  severity13,14,16 and amount of symptom  reduction17,18, quality of ADHD care, such 
as medication  doses15,17,18, adverse  events19, and concomitant  medication11, and factors related to parents or 
families, such as belief in  treatment12, poor family  support20, and family history of  ADHD14. In this study, we 
selected sex, age at first OROS-MPH prescription, clinician specialties, mean daily dosage prescribed in the first 
3 months, and concomitant medication in the first 3 months.
Patient were divided into three age groups as follows: 6–12 years of age (elementary school students), 
13–15 years of age (junior high school students), and 16–17 years of age (high school students or junior high 
school graduates) according to the Japanese school system.
The mean daily dosage prescribed in the first 3 months was calculated by dividing the sum of the total pre-
scription in the first 3 months by 90 days. The results were divided into three groups: a low-dose group (< 18 mg), 
middle-dose group (18–27 mg), and high-dose group (≥ 27 mg) according to the dosing schedule based on 
approvals granted by the Japanese regulatory  authority21. Clinician specialties were divided into three groups as 
follows: psychiatry/psychosomatic medicine, pediatrics, and others. The reasoning for this division of depart-
ments is that only members of the Japan Pediatric Society or the Japanese Society of Psychiatry are under the 
control of the circulation management committee.
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The types of concomitant medications were divided into six groups: ATX, antipsychotics, hypnotics, antide-
pressants, antiepileptics, and anxiolytics (see Supplementary Table S2 online).
Statistical analysis. The estimated prescription rate of OROS-MPH was calculated, as well as the actual 
prescription rate in the target group, which was the population who received the prescription from December 
2007 to April 2016. The estimated prescription rate for the whole population (from 6 to 17 years) was calculated 
by correction for the population statistics issued by the statistics bureau of  Japan22. Kaplan–Meier survival curves 
were used to estimate the continuing prescription of OROS-MPH.
We used multivariable logistic regression analysis to assess the association between risk factors and poor 
adherence. We identified ten possible risk factors (Table 1) and divided patients into two groups: poor adherence 
(MPR below 0.5) and good adherence (MPR above 0.5). The logistic regression analysis was conducted using 
IBM SPSS Statistics version 22 (IBM, Armonk, NY, USA). The analyses were two-tailed, and P values < 0.05 were 
considered statistically significant.
We also conducted sensitivity analysis to ensure the robustness of the analysis. We identified two factors 
from the literature: ADHD severity and adverse events. ADHD severity was thought to interfere with the mean 
daily dosage prescribed in the first 3 months, whereas adverse events are thought to interfere with concomitant 
hypnotic use. The OR for reduced adherence and the ratio of patients who might have possible confounding 
Table 1.  Demographic characteristics of the participants. MPR, medication possession ratio; N, number; 
OROS-MPH, osmotic-release oral system methylphenidate hydrochloride; SD, standard deviation.
N (%) MPR (Mean, SD) MPR < 0.5 (N, %) MPR ≥ 0.5 (N, %)
Total 1353 (100%) 0.51 (± 0.32) 591 (43.7%) 762 (56.3%)
Sex
Male 1141 (84.3%) 0.53 (± 0.32) 469 (41.1%) 672 (58.9%)
Female 212 (15.7%) 0.43 (± 0.33) 122 (57.5%) 90 (42.5%)
Age at their first OROS-MPH prescription
Mean, SD 9.65 (± 2.85), Median 9
6–12 years old 1084 (80.1%) 0.52 (± 0.32) 460 (42.4%) 624 (57.6%)
13–15 years old 225 (16.6%) 0.50 (± 0.32) 106 (47.1%) 119 (52.9%)
16–17 years old 44 (3.3%) 0.43 (± 0.33) 25 (56.8%) 19 (43.2%)
Clinician specialties
Psychiatry and Psychosomatic Medicine 45 (3.3%) 0.45 (± 0.36) 25 (55.6%) 20 (44.4%)
Pediatrics 151 (11.2%) 0.54 (± 0.32) 57 (37.7%) 94 (62.3%)
Others 1,157 (85.5%) 0.51 (± 0.32) 509 (55.2%) 648 (44.8%)
Mean daily dosage prescribed in the first 3 months
Low (< 18 mg) 653 (48.3%) 0.43 (± 0.32) 348 (53.5%) 305 (46.7%)
Middle (18–27 mg) 515 (38.1%) 0.58 (± 0.32) 183 (35.5%) 332 (64.5%)
High (≥ 27 mg) 185 (13.7%) 0.61 (± 0.29) 60 (32.4%) 125 (67.6%)
Concomitant use of other medications in the first 3 months
Atomoxetine
Non-combination group 1139 (84.2%) 0.54 (± 0.32) 454 (39.9%) 685 (60.1%)
Combination group 214 (15.8%) 0.38 (± 0.34) 137 (64.0%) 77 (36.0%)
Antipsychotic
Non-combination group 1149 (84.9%) 0.52 (± 0.32) 485 (42.2%) 664 (57.8%)
Combination group 204 (15.1%) 0.47 (± 0.35) 106 (52.0%) 98 (48.0%)
Hypnotic
Non-combination group 1296 (95.8%) 0.52 (± 0.32) 554 (42.7%) 742 (57.3%)
Combination group 57 (4.2%) 0.41 (± 0.35) 37 (64.9%) 20 (35.1%)
Antidepressant
Non-combination group 1322 (97.7%) 0.51 (± 0.32) 578 (43.7%) 744 (56.3%)
Combination group 31 (2.3%) 0.55 (± 0.36) 13 (41.9%) 18 (58.1%)
Antiepileptic
Non-combination group 1343 (99.3%) 0.51 (± 0.32) 588 (43.8%) 755 (56.2%)
Combination group 10 (0.7%) 0.63 (± 0.37) 3 (30.0%) 7 (70.0%)
Anxiolytic
Non-combination group 1352 (99.9%) 0.51 (± 0.32) 590 (43.6%) 762 (56.4%)
Combination group 1 (0.1%) 0.08 0 (0.0%) 1 (100.0%)
4
Vol:.(1234567890)
Scientific Reports |         (2021) 11:1707  | https://doi.org/10.1038/s41598-021-81416-z
www.nature.com/scientificreports/
factors were determined from the  literature16,19,23,24. Sensitivity analysis was performed using the method pro-
vided by Fox et al.25.
Results
Estimated prescription rate. During the period from the launch of OROS-MPH in Japan (December 
2007) to the last month of data acquisition from the Japan Medical Data Center (JMDC; April 2016), the esti-
mated prescription rate gradually increased from 0.003 to 0.23% (Fig. 1).
Prescription patterns. This study included individuals who first started OROS-MPH medication for 
ADHD between December 2007 and May 2015. Table 1 shows the characteristics of the participants, which 
are summarized using descriptive statistics (mean, standard deviation, percentage). Prescription durations are 
plotted as a Kaplan–Meier survival curve in Fig. 2. The prescription patterns varied and the mean medication 
possession ratio (MPR) was 0.51 ± 0.32 (Table 1), despite the strict control of the circulation management com-
mittee. In our study, only 8.6% of patients (116 of 1353) had no gap period at all, whereas 51.9% (702 of 1353) 
had a gap period of more than 3 months. Of those with a gap less than 2 months (535 patients), 95.7% (512 
patients) resumed the medication and 99.4% (532 patients) had an MPR exceeding 0.5. In contrast, of those with 
a gap more than 3 months (702 patients), only 17.9% (125 patients) resumed the medication and 16.2% (114 
Figure 1.  Prevalence estimates of OROS-MPH in the Japanese population aged 6–17 years. Prevalence 
estimates were corrected with population statistics issued by the statistics bureau of Japan (27). OROS-MPH, 
osmotic-release oral system methylphenidate hydrochloride.
Figure 2.  Kaplan–Meier survival curve for prescription continuance.
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patients) had an MPR exceeding 0.5. Moreover, 90.8% of the patients with an MPR greater than 0.5 (692 of 762) 
continued to take the medication until the end of the follow-up period. Based on these results, we defined an 
MPR greater than 0.5 as an indicator of adherence and a gap of more than 3 months (GAP3M) as an indicator 
of discontinuation (Fig. 3).
Multivariable logistic regression. The results of the multivariable logistic regression are shown in 
Table 2. For patient characteristics, female patients were more likely to show poor adherence than male patients 
(odds ratio [OR], 0.565; 95% confidence interval [CI], 0.414–0.773; P = 0.000). The mean MPR became smaller 
as the age at first prescription increased, but there was no statistically significant effect of age on the mean MPR. 
In addition, clinician specialties were not found to be associated with adherence.
Regarding the mean daily dosage prescribed in the first 3 months, adherence was likely to be poor if 
patients were prescribed doses lower than 18 mg per day and was significantly worse than if they were pre-
scribed 18–27 mg per day and ≥ 27 mg per day (OR, 1.986; 95% CI, 1.554–2.536; P = 0.000; OR, 2.499; 95% CI, 
1.731–3.608; P = 0.000, respectively).
In terms of the types of concomitant medication in the first 3 months, concomitant use of ATX (OR, 0.376; 
95% CI, 0.273–0.517; P = 0.000) or hypnotics (OR, 0.536; 95% CI, 0.291–0.985; P = 0.045) was significantly 
associated with poor adherence.
Sensitivity analysis. The results of the sensitivity analysis are shown in Supplementary Table S1 online. 
Considering the calculated original risk ratio of 1.54, ADHD severity was not considered to have a significant 
effect on the relationship between adherence and the mean daily dosage, even in the most plausible pattern (1.6 
for the estimated risk ratio of the confounding factor, about 60% for the proportion of patients who use OROS-
MPH more than 18 mg per day and about 50% for the proportion of patients who use OROS-MPH less than 
18 mg per day). Therefore, the severity of ADHD was not considered to interfere with the results.
Regarding the effect of adverse events on the relationship between adherence and concomitant hypnotic 
use, the adjusted risk ratio was 1.46 in the most plausible pattern (1.5 for the estimated risk ratio of the con-
founding factor, 70% for the proportion of the patients in the concomitant hypnotic use group, and 60% in the 
non-concomitant group). Considering the original risk ratio of 1.52, it is necessary to be cautious about the risk 
of the occurrence of adverse events in relation to adherence and the concomitant use of hypnotics, and further 
consideration of this aspect is needed.
Discussion
First, this study revealed the actual status of OROS-MPH prescription. The trend for a gradual increase in pre-
scription rates is similar to that of other  countries26–29. However, the prevalence of ADHD drug use in pediatric 
patients was lower in Japan (0.4%)30 than in Norway and the United States (1.4–5.3%)31,32 but similar to that in 
Italy, France, and the UK (0.2–0.5%)33–35. In addition, the share of OROS-MPH in 2014 is lower in Japan (64%)30 
than in Germany, the UK, and Norway (75–100%)32,33,36. Thus, both the prescription of ADHD drug and the 
share of OROS-MPH are low in Japan.
Figure 3.  Participants’ flow diagram. aNew users: patients who had not been prescribed MPH within 1 year 
prior to their first prescription month during our observation period. bNo diagnosis of narcolepsy: patients 
who were prescribed OROS-MPH were chosen. MPH, methylphenidate hydrochloride; OROS-MPH, osmotic-
release oral system methylphenidate hydrochloride.
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One of the reasons for this situation in Japan could be the strict control of OROS-MPH prescription by the 
circulation management committee to limit the qualification of prescribers and the prescription period. Another 
possible reason is the indication for the first-line drug of ADHD medication in the Japanese  guidelines8. Both 
OROS-MPH and ATX are equally listed as first-line drugs, in contrast to other guidelines that recommend 
psychostimulants as first  choice37–39. Although there are differences in efficacy and tolerability among ADHD 
 medications40,41, Japanese physicians may prefer ATX for the initial drug because it has no restriction.
Second, we revealed the erratic prescription patterns of OROS-MPH and analyzed the possible factors that 
could predict the risk of low adherence in the early stage of the OROS-MPH prescription. This erratic pattern 
could be caused by patients forgetting to take the medication, intentional discontinuation, or “drug holidays”. 
The term “drug holiday” refers to the deliberate interruption of pharmacotherapy for a defined period and for 
a specific clinical  purpose42. Although guidelines recommend patients take “drug holidays” when the use is 
extended over a long  period8,39, some patients take these holidays on weekends or during school holidays from 
the early stage of the treatment.
The mean MPR in this study was 0.51 ± 0.32. This is similar to the mean MPR of 0.52 ± 0.30 for extended-
release stimulants in  Texas11 but less than the mean MPR of 0.64 found in the  Netherlands43. Common adherence 
thresholds in previous studies were 0.811,43,44 or 0.745. However, as shown in our results, 90.8% of those with an 
MPR greater than 0.5 continued to take their medication until the end of the follow-up period. Therefore, we 
defined an MPR greater than 0.5 as an indication of adherence.
Among possible risk factors for low adherence detected in our study, sex differences had a statistically signifi-
cant influence on adherence. Compared with girls, boys with ADHD have a tendency to show more externalized 
Table 2.  Risk factors related to adherence during the follow-up period among new users of OROS-MPH 
(n = 1353). P values in bold indicate a significant difference from the reference group at the α = 0.05 level. CI, 
confidence interval; MPR, medication possession ratio; OR, odds ratio; OROS-MPH, osmotic-release oral 
system methylphenidate hydrochloride; Ref, reference.
OR 95% CI to P value P value
Sex
Male Ref Ref
Female 0.5650 0.414–0.773 0.0000
Age at first OROS-MPH prescription
6–12 years old Ref Ref Ref
13–15 years old 0.7980 0.583–1.093 0.1600
16–17 years old 0.5420 0.275–1.069 0.0770
Clinical departments
Psychiatry and Psychosomatic Medicine Ref Ref Ref
Pediatrics 1.8610 0.915–3.785 0.0860
Others 1.4380 0.765–2.706 0.2600
Mean daily dosage prescribed in the first 3 months
Low (< 18 mg) Ref Ref Ref
Middle (18–27 mg) 1.9860 1.554–2.536 0.0000
High (≥ 27 mg) 2.4990 1.731–3.608 0.0000
Concomitant use of other medications in the first 3 months
Atomoxetine
Yes 0.3760 0.273–0.517 0.0000
No Ref Ref Ref
Antipsychotic
Yes 0.7720 0.559–1.066 0.1160
No Ref Ref Ref
Hypnotic
Yes 0.5360 0.291–0.985 0.0450
No Ref Ref Ref
Antidepressants
Yes 1.3710 0.551–3.411 0.4980
No Ref Ref Ref
Antiepileptic
Yes 4.0850 0.644–25.906 0.1350
No Ref Ref Ref
Anxiolytic
Yes 0.0000 0.0000 1.0000
No Ref Ref Ref
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 symptoms46. Although OROS-MPH can reduce both externalized and internalized  symptoms19, improvements 
in externalized symptoms are more readily noticed by caregivers. Therefore, boys may more easily perceive the 
effects of the medication and thus be more likely to continue to take it, as shown in our results.
Regarding a mean daily dosage lower than 18 mg per day, an insufficient treatment effect due to an insuf-
ficient dose might be the reason for lower  adherence47. Although the occurrence of adverse events might affect 
adherence, the adverse events that occur in the short term are mostly non-serious48,49 and lead to withdrawal 
in less than 10% of the patients who experience  them49. In addition, lower doses are usually less likely to cause 
adverse events compared with higher doses.
In terms of concomitant medication, only ATX and hypnotics were linked to adherence. The common rea-
sons for the prescription of concomitant ADHD medications are an inadequate response and intolerance to 
the previous  treatment50. Therefore, the patients who were prescribed ATX in the early stage could be in the 
process of treatment switching or augmentation. Patients undergoing switching or augmentation are likely to 
have lower adherence because of the risk of additive adverse effects caused by the combination use. Therefore, 
it is understandable that the patients with concomitant ATX use had lower adherence.
Patients with concomitant psychotropic use had lower MPRs in our study. However, only hypnotics exhibited 
a statistically significant association with adherence. Sleep disturbances can appear as ADHD  symptoms51–53. 
Therefore, patients with concomitant hypnotic use in the early stage are presumed to originally have had moder-
ate or severe sleep problems. OROS-MPH may worsen sleep status as an adverse  effect54,55, which may negatively 
affect adherence.
There are limitations to the use of the JMDC dataset. It is one of the largest claims databases in Japan but 
includes only 1–2% of all Japanese inhabitants. Additionally, all participants were recipients (or the family 
members of recipients) of employee’s health insurance (Kenkō-Hoken). Therefore, there is a potential for bias 
in socioeconomic and family backgrounds, which could affect  adherence12,14,20. In addition, there is a lack of 
clinical detail in the database, such as ADHD symptoms and severity, incidence of adverse events, and coexist-
ing psychiatric diseases. Therefore, it was not possible to determine whether adherence was due to remission 
of ADHD, ineffectiveness of medication, or aggravated coexisting psychiatric diseases. Thus, we evaluated the 
effect of these factors by conducting sensitivity analysis. Another limitation is that this database represents the 
prescription records and not the actual oral intake records. Thus, there is a possibility that patients did not take 
the medication, even with the prescription. These limitations should be considered in future studies.
Despite these limitations, the findings of our study reveal the current state of pharmacotherapy for ADHD 
using OROS-MPH in Japan and provide useful insights into its resolution. Due to the increased prevalence of 
ADHD and use of psychostimulants, the inappropriate use of and low adherence to psychostimulants have been 
major problems in Japan. Appropriate medications for young ADHD patients are important not only to improve 
ADHD symptoms, but also to prevent the resultant disabilities and difficulties in their daily lives.
This is the first study to provide clinically important evidence of the relationship between adherence and the 
possible risk factors in OROS-MPH treatment for children and adolescents with ADHD in Japan using a large-
scale claims database. These results can help clinicians to predict the risk of poor adherence in the early stage of 
treatment and improve not only patients’ symptoms, but also their quality of life.
Data availability
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